<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 374 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page373.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=374">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 374 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 374</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=374"><img src="../thumb/374.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Biologicals - 26                                                               2020-04 / 337
       (S2) POWD.FOR INJ. 43/30.1/0541.1 000 CCID  50 CAM-70 strain/0,5 ml.  Dosage: Treatm.to be init.& supervis.by exper. physic. Do not shake   to cytotox. agents in periph.bld.progenit.cell mobilisat., assessm.of
       722290-001: 5x10 dos.vials + dil., R1 522,22  excessiv. Pre-fill.syr.to reach room temp.bef.admin.  progenit.cell yields, leukaphores. not to be perform.in donors who are
       Dosage: Recomm.age 9 mnths. Booster at 18 mnths. Addit.dos.at   Adults: Admin.6 mg (singl.pre-fill.syringe) as subcut. inj. approx.24 hrs.  on anticoag./with known haemostas.defects., safety & effic.in norm.
       6 mnths.of age recomm.for HIV posit.pts.  foll.cytotox.chemother. Recomm. for each chemother.cycle.  donors &lt;16 yrs & &gt;60 yrs. not assess., immunologic.interacts.betw.
       0,5 ml by SC inj. Prefer.admin.site is upper arm.   Contraindications: Hypersens.to E-coli deriv. prot.  alogeneic PBPC graft & recipient poss.assoc.with incr.risk of ac. &
       Contraindications: Act./develop.ac.resp.infect., act. untreat.TB,   Side effects: Splen.rupt., bone pain, allerg.-type reacts.incl.ana-  chron. Graft vs Host dis.compar.to bone marr. transplantat., monit.ab-
       ac.infect.dis., leukaem., sev. anaem., other sev.dis.of bld syst., sev.  phylax., naus, arthral., myalg., musc.-skelet./neck/inj.site/chest pain,   sol.neutrophil count closely in HIV infect.pts., consid. appropr.treatm.
       ren.funct. impairm., decompensat.heart dis., cell-mediat. immune   headache, cough/fev.& dyspn.in assoc.with radiolog.signs of pulm.  of known underly. bone infiltrating infect./malign.
       defic.states, kanamycin/ erythromyc. allergy, pregn., other concom.  infiltrates/pulm.funct.deteriorat.& incr. neutrophil count are poss.  Drug interactions: Li poss.potent.eff.
       childhood vaccin., intravasc.admin.  prelimin.signs of adult resp. distress.syndr.(ARDS), leucocytos., mild   See also MDR page 143.
       Side effects: Common: Burn./sting.at inj.site, fev. Uncommon:   to mod elev.in uric acid/alkal.phosphat.& lact. dehydrogen., Sweet’s
       Skin rash, allerg.reacts.incl.itch. /swell./ redness./tendern., ma-  syndr.(ac.febrile dermatos.), cutan. vasculit.  OCTAGAM, Octapharma [P/S]
       laise, headache, cough, pharyngit., coryza. Rare: Thrombocyto-  Warnings and special precautions: Consid. splen. rupt.if pts.   Human normal immunoglobul.G
       pen. purpura, anaphylact.react., sev.& extens.swell./ blister./pain   report left upper abdom.pain/ shoulder tip pain, may prom.growth   Indications: Replacement ther: Prim. immunodefic. syndr.incl.con-
       at inj.site, encephalit./meningo-encephalit., convuls.accompan.  of myeloid cells incl.malign.cells in vitro & simil.effs.poss.on some   genit. agammaglobulinaem. & hypogammaglobuliaem./ common-
                                                                  variable immunodefic./sev.combin. immunodefic., second.hypogam-
       fev.in suscept.pts.           non-myeloid cells in vitro, admin.approx.24 hrs. aft./14 days bef.ad-
       Warnings and Special precautions: Antibody resp. in endogen./  min.of cytotox.chemother., incompat. with sod.chlor.sol., concom.use   maglobulinaem.in chron.lymphocyt.leukaem.& multip.myeloma with
                                                                  repeat. bact.infects., childr.with congenit.AIDS with entry lev.CD4+
       iatrogen.immunosuppress.may be insuffic., convuls.hist.in childr.&   with any chemother.agent not eval., no adeq.data in pregn./ use in   3
       postpone vaccinat. until aged 2 yrs., avoid contact.with disinfects. as   childr.& adolesc.und.18 yrs., lactat., safety & effic.not investig.in pts.  count of 200/mm  or more who have repeat.bact.infects.
                                                                  Immunomodulat.eff: Idiopath.thrombocytopen. purpura (ITP) in adults/
       they inactiv.vacc., allow swab.skin to dry bef.admin., delay.vaccinat.   with ac.leukaem.receiv. myelosuppress. ther./myelodysplast.syndr./
       for at least 3 mnths.follow.admin.of gammaglobul. /bld. transfus.as   chron. myelogen. leukaem./second.AML, pts.receiv.high dos. chem-  childr.at high risk of bleed./ prior to surg.to correct platel.count, al-
                                                                  logen.bone marrow transplantat., Kawasaki dis.
       vacc.fail.poss.due to passively acquir. measles antibod., adrenaline   other., safety & effic.for bld.progenit. cells mobilis.in pts./healthy
       to be avail.in case of anaphylact.reacts.  donors not adeq.eval., reproduct.toxic.in animals, take care distin-  (S4) SOL FOR INJ. 34/30.2/0501.50 mg/ml.
                                                                  713089-001: 50 ml, R1 536,69
       Interactions: Corticoster./other immuno-suppress./concom.radio-  guish. diagnos.of blast transformat.of chron.myeloid leukaem.from
       ther.may interfer with optim.immune respon.developm.  ac.myeloid leukaem., discont. treatm.in case of prelim.S&S of ARDS,   713090-001: 100 ml, R3 073,37
                                                                  713098-001: 200 ml, R6 146,75
       MENACTRA, Sanofi Aventis [P/S]  reg. platel./haematocrit.monit., not to be used to incr. cytotox.chem-  Dosage: Bring to room/body temp.bef.use., use infus.line filter of
       Meningococcal (serogroup A) polysaccharide 4,0 µg, meningococ-  other.dos.beyond est.dos.regim., sickle cell dis., monit.poss.splen.  not less than 0,2 micrometer (micron), dos.& dos. regim.depend.on
                                     enlargem./vaso-occlus.cris.in pts.with sickle cell dis., perm. discont.
       cal (serogroup C) polysaccharide 4,0 µg, meningococcal (serogroup   in pts.exper.ser.allerg.react.  indicat., infus.IV at init.rate of 0,75 - 1,0 ml/min or 15 drops/ min.for
       Y) polysaccharide 4,0 µg, meningococcal (serogroup W-135) poly-  Drug interactions: Safety & effic.not eval.in pts. receiv.chemother.  15 min.follow.by 1,2-1,5 ml/min or 25 drops/min.for next 15 mins., if
       saccharide 4,0 µg/0,5 ml.     assoc.with delay. myelosuppress., concom.5-fluorouracil/other anti-  well tolerat. grad.incr.the rate of admin.to a max.of 3,0 ml/min or 54
       Indications: Act.immunisat.in indiv.9 mnths.-55 yrs. for prevent.  metabolit.potent.myelosuppress.in animals, interacts. with other   drops/min.for remain.of infus.
       of invas.dis.caus.by Neisseria meningitidis serogroups A, C, Y and   haemopoiet.growth fact.& cytokines./Li not investig.  Replacem.ther.in prim.immunodefic.syndr: Dos. regim.should
       W-135, contr. of meningococc.outbreaks, serogroup C antibody resp.   See also MDR page 142.  achieve trough lev.of IgG (meas. bef.next infus.) of at least 4-6 g/l.
       boost in subj.primed with a monoval.C conjug. vacc.        3-6 mnths are reqd.aft.init.ther.for equilibrat.to occur. Recomm.
       (S4) SOL.FOR INJ, 44/30.1/1064.  NEUPOGEN, Amgen [P/S] &   start.dos: 0,4 - 0,8 g/kg depend.on circumstanc. follow.by 0,2 g/kg
       720708-001: 1x0,5 ml; R698,53  Filgrastim (r-metHu G-CSF).  every 3 wks., dose reqd.to achieve trough lev.of 6 g/l is 0,2 - 0,8 g/
       Dosage: 0,5 ml dos.IM admin.only.  Indications: Reduct.in neutropen.durat.& febrile neutropen.in pts.  kg per mnth., dos.interv.when steady state reach.var.from 2 - 4 wks.
       Prim.immunisat: Adults & childr 2-55 yrs: Sngl. IM 0,5 ml dos.   receiv.cytotox.chemother.for malign.(except.chron.myeloid leukaem.&   Replacem.ther.in second.immunodefic: Recomm. dos: 0,2 -
       Childr.9-23 mnths: Give as 2-dos. series at least 3 mnths.apart.  myelodysplast. syndr.) & reduct.of neutropen. durat. & clinic.sequel.in   0,4 g/kg every 3-4 wks.
       Contraindications: Postpone immunis.in mod./ sev. febrile &/ac.dis.  pts.undergoing myeloablative ther.foll.by bone marr.transplant, sev.   Idiopath.thrombocytopen.purpura: Ac. episodes: 0,8 - 1,0 g/
       Side effects: Loc.reacts., trans.fev.in young childr., irritab., drowsin.,   congenit./cycl.or idiopath.neutropen.with ANC &lt;0,5x10 /l, autolog.  kg on day 3 if necess.or 0,4 g/kg dly for 2-5 days., treatm.can be
                                                            9
       headache, malaise, arthralg., diarrh., anorex., chills, fev., fatig., vomit.,   periph.bld.progenit.cells mobilisat. alone or foll.myelosuppress.chem-  repeat.if relapse occurs.
       rash, hives, seiz., hypersens.reacts., Guillain-Barré syndr., paraesthes.,   other. in order to acceler. haematopoiet.recov.by infus. such cells aft.   Kawasaki disease: 1,6 - 2,0 g/kg in div.dos.over 2-5 days or 2
       vasovag.syncope, dizzin., convuls., fac.palsy, ac.disseminat. encepha-  myelosuppress./myeloablative ther., mobilis. periph.bld.progenit.cells   g/kg as sngle dos. Admin.concom. treatm.with acetylsalicyl.acid.
       lomyelit., transv.myelit., myalg.  in norm donors, advanc. HIV infect.& neutropen.to allow sched. dos.   Allogen.bone marr.transplantat: Indiv., IV immunoglobul.  treatm.
       Warnings and special precautions:. Not for act. infect.treatm.,   of anti-retrovir.meds.  may be used as part of condit. regim.& aft.transpl. Recomm.start.
       low-grade fev.does not constit. contraindicat., no protect.against   (S4) INJ, Z/30.4/190, 32/30.4/0032,0033  dos: 0,5 g/kg/wk.
       other micro-organ, not all suscept.indiv.protect., indiv.with funct./   791199-010: 30 MU/1 ml, 5x1 ml vials, R6 026,21  Contraindications: Hypersens.to human immunoglobul. esp.pts.
       anatomic.asplenia may prod.immune respon., antibody respon.to   894081-001: 30 MU/0,5 ml, 5x pre-filled syr, R4 336,87  with antibod.against IgA., selective IgA defic.where IgA defic.is the
       diphther.tox.may occ. but do not consid.as a immunis.agent against   894087-002: 48 MU/0,5 ml, 5x pre-filled syr, R6 703,99  only abnormal. of concern, safety in pregn.& lactat. not est.
       diphther., thrombocytopen./bleed.disords., immunosuppress. treatm.  Dosage: Est.cytotox.chemother: Recomm.dos: 5 µg/kg/day. Do   Side effects: Allerg. & hypersens.type reacts., headache, dizzin.,
       decr.immune response, pts. prev.diagnos.with Guillain-Barré syndr.   not admin.within 24 hrs.of cytotox. Chemother.or bone marrow infus.   chills, back/chest pain, fev., cutan. react., N&V, diarrh., abdom.pain,
       (GBS) may be at incr. GBS risk, if MENACTRA & DTaP vacc. are to   Admin. as dly SC inj/IV infus.dil.in 5% gluc.sol.over 30 mins. Cont.  anaphylact. shock./reacts., revers.asept. meningit., incr. in ser.crea-
       be administ.at 4-6 yrs of age give pref. to simultan.admin of the   till expect.nadir is passed & neutrophil count recover.to norm.range   tin.&/ac.ren.fail., stroke, deep vein thrombos., leukopen., haemolyt.
       2 vaccs./admin. MENACTRA prior to DTaP vacc., do not admin.  (±14 days). Treatm. durat.may be up to 38 days in ac.myeloid leukaem   anaem., angioneurot. oed., fac.oed., agitat., cerebrovasc. accid., par-
       by IV inject., caref.pt.hist.to poss.sensitivit./prev. immunisat.hist.,   treatm. Do not dil.with saline sols.  aesthes., MI, tachycard., palpitat., cyanos., thrombos., periph. circulat.
       keep epinephrine avail.in case of anaphylact.reacts., ensure.that   Other indications: See manufacturers lit.  fail., hypotens., hypertens., resp.fail., pulm. embol./oed., bronchosp.,
       proced.are in place to prev.fall.inj.& manage syncop.reacts., un-  Contraindications: To incr.cytotox.chemother. dos. beyond est.  dyspn., cough, eczema, urticar., rash, erythemat. rash, dermatit.,
       known if excret.in breast milk, only admin.dur.pregn.if clearly need.  regimens, sev.congenit. neutropen. with abnorm.cytogenet., sev.  prurit., alopec., arthralg., myalg., fatig., inj.site react., chills, flush.,
       follow.a risks vs.benef.assessm., avoid intraderm./SC admin.as   ren./ hepat. funct., safety in pregn.& lactat.not est., safety & effic.in   hyperhidros., malaise, hepat. enzymes incr., false positive bld.gluc.
       safety & effic.not est.       myelodysplast. syndr./chron. myelogen. leukaem.not est.& not indi-  Warnings and special precautions: Recomm. infus.rate given
                                                                  must be closely follow.& pt. closely monit.dur.infus.period as cert.
       MENOMUNE, Sanofi Aventis [P/S]  cat.in these condits.,safety & effic.of use in neonates in sev. chron.   sev.adv. effs. may be relat.to rate of infus., ensure that pts.are not
       Neisseria meningitidis Groups A, C, Y, W-135 50 µg/0,5 ml.  neutropen.not est.  sensit.to human normalimmunoglobul. by init. inj. slowly(1 ml/kg/
       Indications: Act.immunizat.against invas. meningococ. dis.caus.  Side effects: Sickle cell crisis somet.fatal, trans. posit.bone imag.  hour), monit.pts naive to human normal immunoglobul./pts.switch.
       by groups ,C,Y & W-135, prev.& control outbreaks of group C   changes, mild to mod. musculoskelet. pain, GI disturbs., alopec., neu-  from an alternat. IVIg product/when there has been a long interv.
                                     tropen. fev., mucosit., fatig., dyspn., headache, cough, skin rash, chest
       meningococc. dis.                                          since the prev.infus.dur.first infus.& for 1st hr.aft. 1st infus.to detect
       (S4) POWD.FOR INJ, 38/30.1/0182.  & unspec.pain, gen.weakn., sore throat, stomatit., trans.BP decr., vasc.  potent.adverse eff., observ. all other pts for at least 20 mins.aft. ad-
                                     disords. incl. veno-occlus.dis.& fluid vol.disturbs., allerg. type sympts.,
       708511-001: 1x10 dose vial, R1 542,23                      min., reduce admin.rate/discont.admin.until sympts disappear in
       Dosage: SC admin.only. Safety & effic.bel.2 yrs.not est. Protect.an-  cutan.vasculit., Sweet’s syndr., exacerbat. of rheumatoid.arthrit., in-  case of adv.reacts., implem. std.medic.treatm.in case of shock, IVIg
                                     terstit.pneum./ pulm.oed.& pulm.infiltrat.poss.lead.to resp.fail./ adult
       tibod.lev.within 7-10 days.                                admin.in all pts.requir.adeq.hydrat.prior to init.of infus./ monit.urine
       Prim.immunisat: Adults & childr: Sngl.SC 0,5 ml dos.  resp. distress, urin.abnormalit., splen. enlargem., thrombocytopen.,   output/monit.ser.creatin.lev./avoid concomit. loop diurets., exerc.caut.
       Revaccinat: Sngl.SC 0,5 ml.dos.indicat.for those at high risk partic.  anaem., epistax., inj. site react., hepatomegaly, arthralg., osteoporos.,   in obese pts.& pts. with pre-exist. risk facts.for thrombot.events &
       if 1  vaccinat.when &lt;4 yrs.   rash, exacerbat.of pre-exist.skin disords.eg psorias., proteinur.& hae-  admin.at min.rate of infus.& dos.praticable, consid. discont.in case of
         st
       Contra-indications: Thiomersal hypersens., postpone immunis.  matur., hyperuricaem., low freq myelodysplast. syndr.(MDS)/leukaem.  ren.impairm., in pts.at risk for ac.ren.fail.admin.at min.rate of infus.&
       dur.course of any ac.illn.    in pts. with sev.congenit. neutropen.  dos. practicable.& meas.creatin.lev.for 3 days aft. infus., asept.men-
       Side-effects:.Loc.reacts., trans.fev.in young childr., headache, ma-  Special precautions: Risk vs.benef.in sickle cell dis., safety &   ingit.syndr.(AMS), monit. pts. for S&S of haemolys., passive transmis.
                                     effic.of Neupogen given on same day as myelosuppress.cytotox.
       laise, chills, fev., very rarely IgA nephropathy           of antibod.may interf.with cert.serologic.tests incl. poss. mislead.
       Special precautions:.Not for act.infect.treatm., no protect.against   chemother.not est., not recomm.24 hrs. bef.to 24 hrs.aft.chemother.  positive results, conseq. hypoglycaem. from the inappropr.admin.
       other etiolog.agents, not all suscept.indiv.protect., not indicat.for in-  in view of sensitiv.of rapid.divid.myeloid.cells to myelosuppress. cy-  of insulin/ untreat.cases of true hypoglycaem. where hypoglycaem.
       fts.& childr. und.2 yrs.except as short term protect.of infts.3 mnths.&   totox.chemother., interacts.with other haematopoiet.growth fact.&   state is mask.by false.elev. gluc. reads., measurem.of bld.gluc.must
       old.against group A, immunosuppress. treatm.decr.immune response,   cytokines not investig., spec.care to distinguish diagnos.of blast trans-  be done with a gluc.-specif.meth., transmis.of infect. agents incl.un-
       caref.pt.hist.to poss.sensitivit./prev.immunisat.hist., keep adrenaline   format.of chron.myeloid leukaem.from ac. myeloid leukaem., monit.  known/emerg.viruses & other pathog. cannot be totally excl., effic.
       avail.in case of anaphylact.reacts., lact.as unknown if excret.in breast   of bone density in underly. osteoporot.bone dis.where ther.exceeds   of live attenuat. virus vaccin.poss.impair.for 6 wks.-3 mnths. (up to 1
       milk, avoid intraderm./ IM or IV admin.as safety & effic.not est., anti-  6 mnths., discont.ther.at onset of pulm.signs in assoc. with radiolog.  yr.in case of large dos.)aft. immunoglobul.admin.
       body lev.decline over 2-3 yrs. theref. consid.revaccinat.within 3-5 yrs.  signs of pulm.infiltrat & deterior. pulm.funct.poss.prelim.signs of adult
       if immunisat. indicat.still exist.  resp. distress syndr., heredit.fruct.intol., reg.WBC/ platel. counts &   OMZYTA, MSD [P/S]
                                     haematocrit, high dos.chemother. as improv.tumour outcome not   Not less than 1 000 CCID 50 measles virus, 12 500 CCID 50 mumps virus
       NEULASTIM, Amgen [P/S] &      demonstrat.& intensif. chemother.agents poss.incr.toxic., admin. of   & 1 000 CCID 50 rubella virus/0,5 ml.
       Pegfilgrastim                 sngl./combinat.chemotherapeut.agents known to caus.sev.thrombo-  Indications: Simultan.immunisat.against measles, mumps & rubella
       Indications: Reduct.of neutropen.durat./incid.of febr.neutropen/  cytopen., neutrophil respons. poss. dimin.in pts.with reduc.precursors,   in indiv.12 mnths.of age/old.
       incid.of infect.as manifest.by febrile neutropen. in pts.treat.with   risk vs benef. of contin.ther.in pts.with sev.chron. neutropen. devel.  (S2) POWD.& DIL FOR SUSP FOR INJ, 50/30.2/0576
       cytotox. chemother. for malign.except.in chron. myeloid leukaem.   abnorm.cytogenet., discont.ther. if MDS/leukaem.occur, 12 mnthly   724016-001: 1x3 ml.vial+dil., R191,50
       & myelodysplast.syndr.        morpholog.& cytogenet. bone marr.exam.recomm., excl.causes of   Dosage: Do not mix.with other vacc.in same syringe. Can be giv.at
       (S4) INJ. 42/8.5/0598         trans.neutropen., monit.spleen size reg., safety & effic.in neonates   same time as live atten. varicella vacc.at diff.site.
       713009-001: 6 mg/0,6 ml, pre-fill.syr., R5 171,43  & pts.with auto-immune neutropen. of infancy not est., prior expos.  Admin.0,5 ml of reconstit.vacc.SC pref.in.outer aspect of upper arm.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page373.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>&nbsp;&nbsp;&nbsp;<a href="page378.html">378</a>&nbsp;&nbsp;&nbsp;<a href="page379.html">379</a>
             </td>
             <td width="35%"><a href="page375.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page375.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
